David Morrow, MD
Cardiovascular Disease · Boston, MANPI 1316928039
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Roche Diagnostics International Ltd at 44.4% of the total. Reporting peaked in 2022 at $36,647 and has fallen 92.6% since, to $2,717 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $1430.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics International Ltd$50K
- Merck$23K
- Roche Diagnostics Corporation$16K
- Novartis$11K
- Abbott$9K
- Regeneron$3K
- plus $48 from 3 others
Across 99 payments — averaging $190,781 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$7.3M
- Astrazeneca UK Limited$3.7M
- Pfizer$3.3M
- Roche Diagnostics Corporation$3M
- Amgen$657K
- AstraZeneca$396K
- plus $473K from 5 others
What the payments were for
- Consulting fees$60,79155%
- Speaking & faculty fees$14,17113%
- Travel & lodging$34,52831%
- Food & beverage$2,0522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics International Ltd | 16 | $49,575 |
| Merck | 28 | $23,196 |
| Roche Diagnostics Corporation | 12 | $16,175 |
| Novartis | 9 | $10,563 |
| Abbott | 7 | $8,569 |
| Regeneron | 3 | $3,416 |
| Janssen Research & Development, LLC | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Astrazeneca UK Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RDI Research$16,964
- CD cobas Reagents$10,144
- XIENCE SIERRA$6,122
- ENTRESTO$4,955
- LEQVIO$3,750
- OPTIS$2,250
How this compares
$111,541 in reported general payments places this provider in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $82,556 |
| EliquisApixaban | 42 | $48,588 |
| EntrestoSacubitril/Valsartan | 24 | $30,595 |
| XareltoRivaroxaban | 18 | $28,999 |
| Repatha SureclickEvolocumab | 14 | $21,725 |
| NexlizetBempedoic Acid/Ezetimibe | 20 | $14,188 |
| Ezetimibe | 77 | $3,998 |
| Atorvastatin Calcium | 202 | $2,835 |
| Rosuvastatin Calcium | 51 | $2,109 |
| Metoprolol Succinate | 93 | $2,072 |
| Valsartan | 13 | $571 |
| ClopidogrelClopidogrel Bisulfate | 29 | $351 |
| Lisinopril | 47 | $313 |
| Torsemide | 17 | $287 |
| Potassium Chloride | 12 | $280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $10,563 | $30,59524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.